NCT07873463
Flutemetamol F 18 Injection Formulation Comparison
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Sep 22, 2026 to Sep 30, 2026
- Site details revised at 6 of 6 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Comparison of Standard Uptake Value ratio in frontal and anterior cingulate brain region
Timeframe: 90-100 minutes after product administration
Comparison of SUVr in posterior cingulate and precuneus brain region
Timeframe: 90-100 minutes after product administration
Comparison of SUVr in lateral temporal brain region
Timeframe: 90-100 minutes after product administration
Comparison of SUVr in inferolateral parietal brain region
Timeframe: 90-100 minutes after product administration
Comparison of Standard Uptake Value (SUV) in heart
Timeframe: 0-60 minutes after product administration
Comparison of SUV in liver
Timeframe: 0-60 minutes after product administration
Comparison of SUV in kidneys
Timeframe: 0-60 minutes after product administration
Secondary (27)
Comparison of global brain Centiloid values
Comparison of SUV in heart
Comparison of SUV in liver
Comparison of SUV in kidneys
Comparison of blinded visual image interpretations without quantification
Show 22 moreShow less
Comparison of blinded visual image interpretations with quantification
Comparison of inter-reader agreement of the blinded visual image interpretations without quantification
Comparison of inter-reader agreement of the blinded visual image interpretations with quantification
Safety: Treatment-emergent adverse event [TEAE] incidence
Safety: Changes from baseline in blood hematology
Safety: Change from baseline in serum biochemistry
Safety: changes from baseline in urinalysis
Safety: changes from baseline in blood pressure
Safety: changes from baseline in heart rate
Safety: changes from baseline in respiratory rate
Safety: changes from baseline in temperature
Safety: changes from baseline in general appearance, rated as normal or abnormal by a qualified healthcare provider.
Safety: changes from baseline in examination of the heart, rated as normal or abnormal by a qualified healthcare provider.
Safety: changes from baseline in examination of the lungs, rated as normal or abnormal by a qualified healthcare provider.
Safety: changes from baseline in 12-lead electrocardiograms [ECGs] heart rate
Safety: changes from baseline in 12-lead electrocardiogram [ECG] heart rhythm
Safety: changes from baseline in 12-lead electrocardiogram [ECG] RR interval
Safety: changes from baseline in 12-lead electrocardiogram [ECG] PR interval
Safety: changes from baseline in 12-lead electrocardiogram [ECG] QRS interval
Safety: changes from baseline in 12-lead electrocardiogram [ECG] QT interval
Safety: changes from baseline in 12-lead electrocardiogram [ECG] QTc interval
Safety: changes from baseline in 12-lead electrocardiogram [ECG] notation of abnormalities
Arms and interventions
GE-287 then VizamylOther
VIZAMYL then GE-287Other
Drugs: GE-287, Vizamyl
Sites
6 sites in 1 country